OpenEvidence Launches AI Telemedicine Platform
What happened
OpenEvidence has released its AI-integrated Doctor Dialer™ platform for telemedicine. The system provides a unified interface for doctor-patient calls, messaging, and voicemail with deeply integrated live clinical decision AI. A limited release of the suite has already powered approximately 37 million minutes of patient care communications in the U.S.
Why it matters
- The company was founded in 2022 by Daniel Nadler, whose previous AI analytics firm, Kensho, was acquired by S&P Global for $550 million in 2018. Nadler was reportedly motivated to start OpenEvidence after his grandfather passed away due to a medical error. - The new Doctor Dialer expands on OpenEvidence's core product, an AI-powered medical search engine that provides physicians with evidence-based answers from over 35 million peer-reviewed publications. The platform has achieved a 90 percent score on the United States Medical Licensing Examination (USMLE). - The AI provides real-time clinical decision support during patient calls and automatically generates evidence-based clinical notes from the conversation. The entire platform is designed to be HIPAA-compliant, meeting federal standards for the protection of sensitive patient health information. - OpenEvidence has seen rapid adoption, with over 40% of physicians in the United States using the platform as of July 2025. The company states that this year, one in three Americans will be treated by a physician using its technology. - Access to the platform, including the new Doctor Dialer feature, is offered at no cost to verified U.S. healthcare professionals. The company's growth has been driven by a direct-to-clinician model, with 95% of new users hearing about it from a colleague. - The company has established partnerships with several major medical organizations, including the American Medical Association, the New England Journal of Medicine (NEJM), and the JAMA Network. - In July 2025, OpenEvidence raised $210 million in a funding round led by GV (Google Ventures) and Kleiner Perkins, which valued the company at $3.5 billion.
Key numbers
- A limited release of the suite has already powered approximately 37 million minutes of patient care communications in the U.S.
- - The company was founded in 2022 by Daniel Nadler, whose previous AI analytics firm, Kensho, was acquired by S&P Global for $550 million in 2018.
- The new Doctor Dialer expands on OpenEvidence's core product, an AI-powered medical search engine that provides physicians with evidence-based answers from over 35 million peer-reviewed publications.
- The platform has achieved a 90 percent score on the United States Medical Licensing Examination (USMLE).
What happens next
- The new Doctor Dialer expands on OpenEvidence's core product, an AI-powered medical search engine that provides physicians with evidence-based answers from over 35 million peer-reviewed publications.
- The company states that this year, one in three Americans will be treated by a physician using its technology.
Quick answers
What happened in OpenEvidence Launches AI Telemedicine Platform?
OpenEvidence has released its AI-integrated Doctor Dialer™ platform for telemedicine. The system provides a unified interface for doctor-patient calls, messaging, and voicemail with deeply integrated live clinical decision AI. A limited release of the suite has already powered approximately 37 million minutes of patient care communications in the U.S.
Why does OpenEvidence Launches AI Telemedicine Platform matter?
The company was founded in 2022 by Daniel Nadler, whose previous AI analytics firm, Kensho, was acquired by S&P Global for $550 million in 2018. Nadler was reportedly motivated to start OpenEvidence after his grandfather passed away due to a medical error. The new Doctor Dialer expands on OpenEvidence's core product, an AI-powered medical search engine that provides physicians with evidence-based answers from over 35 million peer-reviewed publications. The platform has achieved a 90 percent score on the United States Medical Licensing Examination (USMLE). The AI provides real-time clinical decision support during patient calls and automatically generates evidence-based clinical notes from the conversation. The entire platform is designed to be HIPAA-compliant, meeting federal standards for the protection of sensitive patient health information. OpenEvidence has seen rapid adoption, with over 40% of physicians in the United States using the platform as of July 2025. The company states that this year, one in three Americans will be treated by a physician using its technology. Access to the platform, including the new Doctor Dialer feature, is offered at no cost to verified U.S. healthcare professionals. The company's growth has been driven by a direct-to-clinician model, with 95% of new users hearing about it from a colleague. The company has established partnerships with several major medical organizations, including the American Medical Association, the New England Journal of Medicine (NEJM), and the JAMA Network. In July 2025, OpenEvidence raised $210 million in a funding round led by GV (Google Ventures) and Kleiner Perkins, which valued the company at $3.5 billion.
